Date: 2015-11-10
Type of information: Nomination
Compound:
Company: Epirus Biopharmaceuticals (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On November 10, 2015, Epirus Biopharmaceuticals, a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), announced that Vincent E. Aurentz has joined the Company as Chief Business Officer. Vincent Aurentz most recently served as the President of HemoShear Therapeutics, where he oversaw the scientific and business development efforts including collaborations with global organizations such as Pfizer, Eli Lilly, Janssen R&D and Children's National Health System. Prior to joining HemoShear Therapeutics, Mr. Aurentz was Executive Vice President and member of the Executive Management Board at Merck KGaA (Merck Serono) where he directed R&D programs, portfolio strategy and headed all deal activity and venture investments. He is a former Executive Vice President at Quintiles, Co-founder and Managing Director of a venture capital and advisory business and started his career at Andersen Consulting (now Accenture).
Financial terms:
Latest news:
